

**SINGAPORE HSA APPROVES EISAI'S HALAVEN[®] (ERIBULIN MESYLATE)
INJECTION FOR TREATMENT OF METASTATIC BREAST CANCER**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Singapore Health Sciences Authority (HSA) approved the company's novel anticancer agent HALAVEN[®] (generic name: eribulin mesylate) injection on February 9 (Singapore local time) for the treatment of patients with locally advanced or meta

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. Halaven® eribulin mesylate

Halaven® is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of patients with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy should have included an anthracycline and a taxane. Halaven® belongs to a class of antineoplastic agents, the halichondrins, which are natural products isolated from the marine sponge *Halichondria okadae*. It is believed to work